GLP-1 Science
GLP-1 and Smoking Cessation Research
Emerging research suggests semaglutide may reduce tobacco use, an unexpected finding still being actively studied. Here...
Eight GLP-1 based medications are now approved, and they are sold under roughly fifteen brand names. That mismatch is why this field confuses people.
The same molecule frequently appears under two names, one approved for diabetes and one for weight management. Once you understand that pattern, the whole landscape becomes readable.
This is the complete list, what each does, and which ones matter in Pakistan.
First, the naming pattern
Manufacturers routinely sell one drug under two brand names.
| Molecule | Diabetes brand | Weight loss brand |
|---|---|---|
| Semaglutide (injection) | Ozempic | Wegovy |
| Semaglutide (tablet) | Rybelsus | — |
| Liraglutide | Victoza | Saxenda |
| Tirzepatide | Mounjaro | Zepbound |
| Dulaglutide | Trulicity | — |
| Exenatide | Byetta, Bydureon | — |
The weight loss brand is normally the same drug at a higher dose. There is no chemical difference.
The approved medications
Semaglutide
The most widely used molecule in this class, made by Novo Nordisk.
Ozempic is the weekly injection for type 2 diabetes, dosed 0.5 mg to 2.0 mg. Wegovy is the weekly injection for weight management at 2.4 mg. Rybelsus is the daily tablet form, approved for type 2 diabetes.
In STEP 1, published in the New England Journal of Medicine, semaglutide 2.4 mg produced an average 14.9 percent body weight reduction over 68 weeks.
Semaglutide also has strong cardiovascular evidence. The SELECT trial showed reduced major adverse cardiovascular events in people with obesity and existing cardiovascular disease but without diabetes.
The oral form is notable for one practical reason. It must be taken on an empty stomach with no more than 120 ml of water, then nothing else for at least 30 minutes. Absorption is poor and easily disrupted.
Tirzepatide
Made by Eli Lilly. Mounjaro for type 2 diabetes, Zepbound for weight management. Weekly injection, 2.5 mg to 15 mg.
Tirzepatide is not strictly a GLP-1 drug alone. It is a dual agonist, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide, a second gut hormone that affects insulin release and how fat tissue stores energy).
In SURMOUNT-1, published in the New England Journal of Medicine, tirzepatide produced average reductions of 15.0 percent at 5 mg, 19.5 percent at 10 mg and 20.9 percent at 15 mg over 72 weeks, against 3.1 percent on placebo.
That 20.9 percent figure is the highest of any approved weight loss medication.
Liraglutide
Also Novo Nordisk. Victoza for type 2 diabetes at up to 1.8 mg, Saxenda for weight management at 3.0 mg. Daily injection.
The SCALE trial recorded 8.4 kg average loss over 56 weeks on Saxenda against 2.8 kg on placebo. The LEADER trial demonstrated cardiovascular benefit in type 2 diabetes.
Its main drawback is dosing burden. Daily injection means 365 a year, which drives high real-world discontinuation.
Dulaglutide
Eli Lilly's Trulicity, weekly injection for type 2 diabetes, 0.75 mg to 4.5 mg.
Its standout feature is the injection device, which has a hidden pre-attached needle requiring no assembly or dose dialling. For needle-averse patients this matters considerably.
The REWIND trial followed 9,901 people for a median 5.4 years and found reduced major cardiovascular events, with most participants not having established cardiovascular disease at enrolment.
Weight loss is modest, around 3 kg at 1.5 mg.
Exenatide
The original. Byetta twice daily, Bydureon weekly extended-release. Derived from a compound found in Gila monster saliva.
Exenatide opened this entire drug category in 2005. It has since been outperformed on every clinical measure by newer options, with typical weight loss of 2 to 3 kg and higher nausea rates. Bydureon additionally causes injection site nodules.
Largely superseded, though still in use by people stable on it.
Orforglipron
Approved by the FDA on 1 April 2026 for weight management, orforglipron is the newest entry and a genuinely different kind of drug.
It is a small-molecule, non-peptide GLP-1 receptor agonist taken as a daily tablet. The distinction from Rybelsus matters enormously in practice: orforglipron requires no food or water restrictions. Rybelsus demands an empty stomach, no more than 120 ml of water, and nothing else for 30 minutes. Orforglipron removes that entirely.
In the ATTAIN-1 phase 3 trial, the highest dose produced average weight loss of up to 12.4 percent over 72 weeks. In ATTAIN-2, in people with obesity and type 2 diabetes, the highest dose produced 10.5 percent alongside an average 1.8 percentage point HbA1c reduction.
Because it is a small molecule rather than a peptide, it does not require the same manufacturing capacity as injectable GLP-1 drugs. That has implications for supply and eventually for price, which is the barrier that matters most in markets like Pakistan.
It carries the standard GLP-1 warnings, including the boxed warning about thyroid tumours.
The pipeline
Several further drugs are in development. None is approved yet, and anything sold as one of these today should be treated with extreme suspicion.
Retatrutide is a triple agonist targeting GLP-1, GIP and glucagon receptors. Its phase 2 results were the most striking yet seen in this field.
CagriSema combines semaglutide with cagrilintide, an amylin analogue that works on a separate fullness pathway.
Survodutide and mazdutide are further dual and multi-agonist candidates in development.
The direction of travel is clear. More receptors, more weight loss, and a decisive shift toward oral delivery.
How they compare on weight loss
| Medication | Typical weight loss | Trial |
|---|---|---|
| Tirzepatide 15 mg | 20.9 percent | SURMOUNT-1, 72 weeks |
| Semaglutide 2.4 mg | 14.9 percent | STEP 1, 68 weeks |
| Liraglutide 3.0 mg | 8.4 kg | SCALE, 56 weeks |
| Dulaglutide 1.5 mg | ~3 kg | SUSTAIN 7, 40 weeks |
| Exenatide | 2 to 3 kg | Various |
These come from different trials with different populations and durations, so cross-comparison is indicative rather than exact. The ranking is consistent, but the precise gaps should not be read as settled.
The shared side effect profile
Every drug here works partly by slowing stomach emptying, so they share a side effect pattern.
Nausea, diarrhoea, vomiting and constipation dominate across all of them. Effects are typically worst after dose increases and settle at a stable dose.
Serious risks are also shared. Pancreatitis and gallbladder disease occur across the class. None is used in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and none during pregnancy.
The broad pattern is that stronger weight loss comes with more gastrointestinal disturbance. There is no option in this class that delivers large results with no digestive cost.
What is actually available in Pakistan
This is the part most lists skip, and it is the part that decides everything for readers here.
None of the medications above is registered for sale in Pakistan. Every unit in the country arrived through import or informal channels.
The consequences are concrete. There is no regulated price, so costs swing with the exchange rate. There is no guaranteed supply, so courses break mid-treatment. There is no straightforward way to verify authenticity, and counterfeit GLP-1 pens have been found in multiple markets globally. And there is usually no clinical supervision attached to an informal purchase.
The duration problem compounds all of this. SURMOUNT-1 ran 72 weeks. STEP 1 ran 68 weeks. Those results describe continuous treatment for well over a year. An import chain that fails at month four does not deliver a proportional share of that result, because appetite returns and restarting means re-escalating from a low dose.
This is the gap a locally registered GLP-1 supplement exists to fill. METASLIM™ is a physician-reviewed sublingual supplement working on the GLP-1 appetite pathway, held under the tongue rather than injected. It is not a pharmaceutical GLP-1 receptor agonist, so none of the trial figures above apply to it and nobody should present them as though they do. What it offers is physician review before dispatch, no cold chain, and a supply that does not depend on imports.
To understand what that pathway does, our page on how GLP-1 support works covers the mechanism. Our guide to Ozempic alternatives goes deeper on the comparison, and what Zepbound is covers the strongest approved option in detail.
The summary
Seven molecules, fourteen brand names, one shared mechanism and a consistent ranking on results.
Tirzepatide leads on weight loss. Semaglutide is the most widely used and has the strongest cardiovascular evidence in people without diabetes. Liraglutide works but requires daily injection. Dulaglutide has the easiest device. Exenatide is largely superseded.
The pipeline points toward more receptors and oral delivery.
And in Pakistan, none of them is registered, which makes availability rather than efficacy the question that actually decides what you can do.
View the program and current pricing to compare a locally available option.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.